Search

Edward M Rudnic

from Georgetown, TX
Age ~69
Get Report
Also known as:
Edward Dr Rudnic, Edward H Rudnic, Megan Rudnic, Edward Rudnie
Phone and address:
105 N Austin Ave APT 4209, Georgetown, TX 78626
(512) 240-5568
Related to:
Annette W Degange, 72Vanessa Ayala, 50Jill M Dorsey, 45Elliot Friedman, 46Justin Woodhull, 41
Connected to:
Aaron Rudnick, 32Agnieszka K Rudnicka, 49Arlene E Rudnick, 98Barbara Rudnicka, 91Benjamin A Rudnick, 56Carmen R Rudnick, 37Christine H Rudnick, 44Christine M Rudnicki, 56Denise C Rudnicki, 66Dennis M Rudnick, 73

Edward Rudnic Phones & Addresses

  • 105 N Austin Ave APT 4209, Georgetown, TX 78626 (512) 240-5568
  • 13517 Maidstone Ln, Potomac, MD 20854 (301) 869-4622 (301) 869-6342
  • 13577 Maidstone Ln, Potomac, MD 20854 (301) 869-6342
  • Rockville, MD
  • 15103 Gravenstein Way, North Potomac, MD 20878 (301) 869-4622 (301) 869-6342
  • Gaithersburg, MD
  • Plainsboro, NJ
  • Boca Raton, FL
  • 15103 Gravenstein Way, North Potomac, MD 20878 (301) 869-6342

Work

Position: Production Occupations

Emails

u***[email protected]

Resumes

Resumes

Edward Rudnic Photo 1

Co-Founder, President, And Chief Executive Officer

View page
Location:
Washington, DC
Industry:
Pharmaceuticals
Work:
Austhera Biosciences
Co-Founder, President, and Chief Executive Officer
Vivreon Biosciences Nov 2015 - Oct 2016
Chairman and Chief Executive Officer
Dispersol Technologies, Llc Nov 2015 - Oct 2016
President and Chief Executive Officer
Qrx Pharma May 2014 - Jan 2015
Former Chief Executive Officer
Qrx Pharma Feb 2012 - Apr 2014
Chief Operating Officer
Education:
University of Rhode Island 1973 - 1982
Doctorates, Doctor of Philosophy University of Rhode Island 1979 - 1982
Doctorates, Doctor of Philosophy University of Rhode Island 1978 - 1979
Master of Science, Masters University of Rhode Island 1973 - 1978
Bachelors, Bachelor of Science, Pharmacy Lynbrook High School 1969 - 1973
Skills:
Pharmaceutical Industry
Biotechnology
Life Sciences
Technology Transfer
Fda
Drug Development
Clinical Trials
Biopharmaceuticals
Regulatory Affairs
Strategic Planning
Clinical Research
Start Ups
Pharmaceutics
Commercialization
Medical Devices
Clinical Development
Patents
Oncology
Gmp
R&D
Validation
Drug Delivery
Cro
Drug Discovery
Infectious Diseases
Regulatory Submissions
Sop
Lifesciences
Analytical Chemistry
Product Launch
Capa
Executive Management
21 Cfr Part 11
Vaccines
Gcp
Ipo
Private Equity
Investor Relations
Strategy and Vision
Venture Fund
Cmc
Regulatory Compliance
Patent Applications
Fda Gmp
Board of Directors
Corporate Compliance
Patent Litigation
Strategic Negotiations
Marketing Management
Fda Audits
Interests:
Economic Empowerment
Politics
Education
Science and Technology
Health
Edward Rudnic Photo 2

President And Chief Executive Officer

View page
Location:
20425 Seneca Meadows Pkwy, Germantown, MD 20876
Industry:
Biotechnology
Work:
Middlebrook Pharmaceuticals
President and Chief Executive Officer
Education:
University of Rhode Island 1973 - 1982

Business Records

Name / Title
Company / Classification
Phones & Addresses
Edward Rudnic
President
QRXPHARMA, INC
1430 Us Hwy 206 SUITE 230, Bedminster, NJ 07921
13517 Maidstone Ln, Potomac, MD 20854
Edward Rudnic
Principal
Technology Council of Maryland Foundation Inc
Medical Doctor's Office
9713 Ky West Ave, Rockville, MD 20850
9210 Corp Blvd, Rockville, MD 20850

Publications

Us Patents

Soluble Form Osmotic Dose Delivery System

View page
US Patent:
6361796, Mar 26, 2002
Filed:
Aug 9, 2000
Appl. No.:
09/634224
Inventors:
Edward M. Rudnic - North Potomac MD
Beth A. Burnside - Bethesda MD
Henry H. Flanner - Montgomery Village MD
Sandra E. Wassink - Frederick MD
Richard A. Couch - Chevy Chase MD
Jill E. Pinkett - Baltimore MD
Assignee:
Shire Laboratories, Inc. - Rockville MD
International Classification:
A61K 924
US Classification:
424473, 424476, 424479, 424480, 424482, 514960
Abstract:
Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Soluble Form Osmotic Dose Delivery System

View page
US Patent:
6514532, Feb 4, 2003
Filed:
Dec 28, 2001
Appl. No.:
10/035077
Inventors:
Edward M. Rudnic - North Potomac MD
Beth A. Burnside - Bethesda MD
Henry H. Flanner - Montgomery MD
Sandra E. Wassink - Frederick MD
Richard A. Couch - Chevy Chase MD
Jill E. Pinkett - Baltimore MD
Assignee:
Shire Laboratories, Inc. - Rockville MD
International Classification:
A61K 924
US Classification:
424473, 424474, 424476, 424479, 424480, 424482, 514960
Abstract:
Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Solid Solution Beadlet

View page
US Patent:
6692767, Feb 17, 2004
Filed:
Sep 18, 1998
Appl. No.:
09/156464
Inventors:
Beth A. Burnside - Silver Spring MD
Charlotte M. McGuinness - Bethesda MD
Edward M. Rudnic - North Potomac MD
Richard A. Couch - Bethesda MD
Xiaodi Guo - Derwood MD
Alexander K. Tustian - Bothell WA
Assignee:
Shire Laboratories Inc. - Rockville MD
International Classification:
A61K 916
US Classification:
424489, 424464, 424465, 424451, 424435, 424490, 5147723, 514784, 514785, 514786, 514951, 514770
Abstract:
Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100Â C. , and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.

Osmotic Drug Delivery System

View page
US Patent:
6814979, Nov 9, 2004
Filed:
Dec 20, 2002
Appl. No.:
10/324187
Inventors:
Edward M. Rudnic - North Potomac MD
Beth A. Burnside - Bethesda MD
Henry H. Flanner - Montgomery MD
Sandra E. Wassink - Frederick MD
Richard A. Couch - Chevy Chase MD
Jill E. Pinkett - Baltimore MD
Assignee:
Shire Laboratories, Inc. - Rockville MD
International Classification:
A61K 924
US Classification:
424473, 424474, 424476, 424479, 424480, 424482, 514960
Abstract:
Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Antiviral Product, Use And Formulation Thereof

View page
US Patent:
7282221, Oct 16, 2007
Filed:
Nov 14, 2005
Appl. No.:
11/273661
Inventors:
Edward M. Rudnic - Potomac MD, US
James D. Isbister - Potomac MD, US
Sandra E. Wassink - Frederick MD, US
Assignee:
Middlebrook Pharmaceuticals, Inc. - Germantown MD
International Classification:
A61K 9/14
A61K 9/00
A61K 9/48
A61K 9/20
A61K 9/16
US Classification:
424489, 424400, 424451, 424464, 424490, 424497, 424502
Abstract:
An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Pulsatile Transdermally Administered Antigens And Adjuvants

View page
US Patent:
20040253249, Dec 16, 2004
Filed:
Apr 2, 2004
Appl. No.:
10/816670
Inventors:
Edward Rudnic - Potomac MD, US
Colin Rowlings - Potomac MD, US
Beth Burnside - Bethesda MD, US
Robert Guttendorf - Gaithersburg MD, US
International Classification:
A61K039/00
US Classification:
424/184100
Abstract:
Methods for triggering immunogenic responses and for eliciting improved immunogenic responses to immunogens in humans or animals through pulsatile transdermal delivery of antigens and adjuvants to the Langerhans cells of the skin, are disclosed.

Once-A-Day (Rna-Polymerase Inhibiting Or Phenazine) - Dihydropteroate Synthase Inhibiting - Dihydrofolate Reductase Inhibiting Antibiotic Pharmaceutical Product, Formulation Thereof, And Use Thereof In Treating Infection Caused By Methicillin-Resistant Staphylococcus Aureus

View page
US Patent:
20100016333, Jan 21, 2010
Filed:
Aug 7, 2007
Appl. No.:
11/890747
Inventors:
Henry H. Flanner - Montgomery Village MD, US
Donald Treacy - Woodbine MD, US
Beth A. Burnside - Bethesda MD, US
Edward M. Rudnic - North Potomac MD, US
International Classification:
A61K 31/496
A61P 31/04
US Classification:
51425411
Abstract:
Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant , or “MRSA,” the products comprising: a combination of at least three different antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics or Phenazine antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of Dihydropteroate Synthase Inhibiting antibiotics, and wherein one of the at least three different antibiotics is selected from the group consisting of Dihydrofolate Reductase Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics, Dihydropteroate Synthase Inhibiting antibiotics, and Dihydrofolate Reductase Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhibitor, preferably a LexA protease cleavage inhibitor.

Once-A-Day Rna-Polymerase Inhibiting And Elongation Factor G (Ef-G) Inhibiting Antibiotic Pharmaceutical Product, Formulation Thereof, And Use Thereof In Treating Infection Caused By Methicillin-Resistant Staphylococcus Aureus

View page
US Patent:
20100120896, May 13, 2010
Filed:
Jul 1, 2009
Appl. No.:
12/459415
Inventors:
Sanna Sander - North Potomac MD, US
Henry H. Flanner - Montgomery Village MD, US
Beth A. Burnside - Bethesda MD, US
Donald Treacy - Woodbine MD, US
Edward M. Rudnic - Potomac MD, US
International Classification:
A61K 31/496
A61P 31/04
A61K 31/438
A61K 31/7088
US Classification:
514 44 R, 51425411, 514278
Abstract:
Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant or “MRSA,” the products comprising: a combination of at least two different antibiotics, wherein one of the at least two different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics and wherein one of the at least two different antibiotics is selected from the group consisting of Elongation Factor G (EF-G) Inhibiting antibiotics (alternatively any or all of the aforementioned RNA-Polymerase Inhibiting antibiotics and Elongation Factor G (EF-G) Inhibiting antibiotics may be in the form of analogues, derivatives, polymorphs, metabolites, pro-drugs, salts, and/or hydrates of any of the foregoing); optionally in further combination with a resistance inhibitor, preferably a LexA protease cleavage inhibitor.
Control profile
Edward M Rudnic from Georgetown, TX, age ~69 Get Report